Plain-English translation of NCT07258771 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether upadacitinib, a new medication, works better when combined with steroids compared to steroids alone for people experiencing a severe flare-up of ulcerative colitis. You would receive the medication over several weeks, starting with an intensive phase and then continuing at a lower dose. The study will compare how well this combination approach helps your symptoms improve.
Severe ulcerative colitis flare-ups can be life-threatening and many patients don't respond well enough to steroids alone. Researchers want to see if adding this medication can help more patients recover faster and avoid hospitalization or surgery.
You likely qualify if…
You likely don't qualify if…
If you qualify for the outpatient arm, you would start with an intensive 5-day phase receiving the medication and steroids at a clinic or treatment center, then continue taking the medication at home for 8 weeks while gradually reducing steroids. Over the next year, you would visit your gastroenterologist regularly, have blood tests, complete daily symptom surveys, and continue the medication at adjusted doses based on how you're doing. The full study lasts about a year.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States